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ABSTRACT 
Calcitriol has a critical role in regulating mineral and bone metabolism in children and adults. 
However, its role in fetal mineral and bone metabolism is not yet well understood. Hence, we 
investigated the role of calcitriol during fetal development using a knockout mouse model 
involving ablation of the Cyp27b1 gene encoding 1α-hydroxylase that converts 25-
hydroxyvitamin D3 to 1,25-dihydroxyvitamin D3 (calcitriol). Specifically, this study compared 
Cyp27b1 null fetuses to wild type (WT) fetuses from heterozygous (Cyp27b1+/-) mothers. Our 
findings showed that Cyp27b1 null fetuses had normal calcium and phosphorus levels in serum 
and amniotic fluid, normal placental mineral transport, as well as normal skeletal ash weight, 
mineral content and bone morphology. The quantitative RT-PCR confirmed the loss of Cyp27b1 
expression in null fetal kidneys, but there were no changes in fetal renal or placental expression 
of calciotropic and phosphotropic genes. Although the calcitriol level in Cyp27b1 null fetuses 
was significantly lower than the WT siblings, it was not undetectable, likely due to placental 
transfer of maternal calcitriol to the fetuses. To investigate this possibility, a preliminary study 
was conducted to assess the fetal mineral and bone metablism of Cyp27b1 null fetuses born from 
Cyp27b1 null mothers. Pilot data showed that these fetuses had normal serum calcium and 
skeletal ash weight and morphology. In summary, our findings herein suggest that calcitriol may 
not play a role in fetal mineral and bone metabolism. However, further studies involving 
Cyp27b1 null fetuses from null mothers are required to conclusively support this conclusion.  
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1 INTRODUCTION 
1.1 Preamble 
This study was done to investigate the role of 1,25-dihydroxyvitamin D3 (calcitriol) in regulating 
mineral homeostasis and bone metabolism in the fetus. Previous studies in our lab and other 
studies suggest that unlike its critical role in infants, children and adults, calcitriol might not be 
required for fetal bone and mineral metabolism. To investigate this hypothesis, we studied mice 
unable to make calcitriol due to ablation of the cytochrome P450 family 27 subfamily B member 
1 (Cyp27b1) gene, which encodes 1α-hydroxylase, the enzyme required to synthesize calcitriol. 
To understand the aim of this project, this introduction will provide background information on 
the specific role of Vitamin D, and its associated hormones, in the regulation of bone and mineral 
metabolism in adults and fetuses. 
 
Throughout this thesis the standard nomenclature for naming genes and proteins will be 
followed. Human genes and proteins will be in all capital letters while animal genes and proteins 
will be in lower case, with the initial capital letter only. Both human and animal genes will be 
italicized, while proteins are in standard font.  
 
1.2 Vitamin D: Metabolism and Mechanism of Action 
Vitamin D3 is derived from the diet or is synthesized in the skin by ultraviolet irradiation of 7-
dehydrocholestrol (1). Vitamin D3 has no biological activity on its own, and the active form of 
vitamin D3, 1,25-Dihydroxyvitamin D3 (1,25(OH)2D3; also known as calcitriol), is produced 
following hydroxylation of the 1st and 25th carbon atoms of vitamin D3 (2). The hydroxylation of 
the 1st and 25th carbons of vitamin D3 occurs in the liver and kidneys, respectively (Figure 1). 
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Figure 1. Vitamin D metabolism pathway. 
Vitamin D3 is converted to its active metabolite, 1, 25-dihydroxyvitamin D3 (calcitriol), 
following hydroxylation in the liver and kidneys. Adapted with permission from (3) Appendix A. 
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In the liver, C-25 of vitamin D3 is hydroxylated to produce 25-hydroxyvitamin D3 (25(OH)D3) 
by the actions of cytochrome P450 (CYP) enzymes such as CYP family 2 subfamily R member 1 
(CYP2R1), CYP family 27 subfamily A member 1 (CYP27A1), and CYP family 2 subfamily D 
member 25 (CYP2D25; (1,2). However, it has been suggested that CYP2R1 is the key enzyme, 
as patients with homozygous mutations of CYP2R1 are known to have low levels of 25(OH)D3 
and classical symptoms of vitamin D3 deficiency (4).  
 
Subsequent to the blood transport of 25(OH)D3 by the vitamin D binding protein, the second 
hydroxylation at C-1 position occurs in the kidney, where 25(OH)D3 is converted into calcitriol 
by the 25(OH)D3 1α-hydroxylase (also known as CYP27B1) enzyme (5). CYP27B1, which is 
predominantly present in the proximal renal tubule (1), is considered the principle enzyme in the 
formation of calcitriol. The physiological importance of calcitriol is evident from human 
disorders such as vitamin D-dependent rickets (VDDR) type I and type II. In VDDR type I, 
where calcitriol is absent, non-synonymous homozygous mutations of CYP27B1 are known to 
cause the phenotype, also referred to as pseudovitamin D deficiency rickets. In VDDR type II, 
inactivating mutations of the vitamin D receptor make it non-functional and lead to the 
phenotype, also known as hereditary vitamin D-resistant rickets. While both conditions cause 
rickets, seizures, hypocalcemia, secondary hyperparathyroidism, they differ in the genetic cause 
and the fact that only VDDR type II causes total scalp and body alopecia in some but not all 
cases (6). 
 
The activity of CYP27B1 and synthesis of calcitriol in the kidney is tightly controlled by actions 
of parathyroid hormone (PTH), fibroblast growth factor 23 (FGF23), and calcium and phosphate 
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concentrations (2,6). Specifically, low calcium increases PTH which stimulates the transcription  
of CYP27B1 and thereby the production of calcitriol, whereas FGF23 and calcitriol inhibit 
CYP27B1 (2). The existence of CYP27B1 at extra-renal sites has also been widely documented 
(7). The extra-renal production of calcitriol in tissues, such as keratinocytes, macrophages, and 
osteoblasts, is controlled by actions of tumor necrosis factor (TNF)-α, interferon (IFN)-γ, and 
interleukin (IL)-1β (1,6). The expression of CYP27B1 has also been documented in fetal 
trophoblasts and maternal decidua (8). 
 
The 24-hydroxylase mitochondrial enzyme, CYP family 24 subfamily A member 1 (CYP24A1) 
is also involved in vitamin D metabolism via hydroxylation of both 25(OH)D3 and 1,25(OH)2D3 
(1). CYP24A1 limits the amount of 1,25(OH)2D3 in target tissues both by accelerating the 
catabolism of 1,25(OH)2D3 to 1,24,25(OH)3D3, resulting in calcitroic acid, and by producing 
24,25(OH)2D3 and 23,25(OH)2D3, thereby reducing the pool of 25(OH)D3 available for 1-
hydroxylation (2,5,9). In humans, CYP24A1 mutations have been reported to have a causal role 
in patients with idiopathic infantile hypercalcemia, providing further evidence of the role of 
CYP24A1 in 1,25(OH)2D3 catabolism (9,10). 
 
The physiological effects of calcitriol are primarily known to be mediated by actions on its 
classical receptor, the vitamin D receptor (VDR) (1). The VDR belongs to the steroid receptor 
family that encompasses retinoic acid, thyroid hormones, sex hormones, and adrenal steroid 
receptors (11). The stereospecific binding of calcitriol to the VDR results in heterodimerization 
with the retinoid X receptors (RXR) (12). Formation of the calcitriol-VDR-RXR complex results 
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in the activation of transcription factors or co-activators, such as TATA binding protein-
associated factors, p160 coactivators and steroid receptor activators (12).  
 
Vitamin D receptors are widely expressed throughout the body in classical target tissues such as 
osteoblasts, enterocytes, distal renal tubule cells, the parathyroid gland, keratinocytes, 
promyelocytes, lymphocytes, the pituitary gland and ovarian cells, to name only a few (5). 
Hence, it has been suggested that calcitriol may have extraskeletal physiological roles; however, 
this remains to be elucidated. The following sections of my thesis will focus on the role of 
calcitriol-VDR signalling in the regulation of mineral homeostasis and bone development in 
adults and fetuses. 
 
1.3 Mineral Homeostasis  
The classical endocrine actions of calcitriol, in concert with PTH and FGF23, are predominantly 
responsible for the regulation of calcium and phosphorus homeostasis (Figure 2; (1). Calcium, 
phosphate, and magnesium are multivalent ions that are vital for many biological and cellular 
functions (13). The imbalance in the maintenance of mineral homeostasis can be manifested by 
numerous clinical symptoms [reviewed in detail elsewhere (14)]. Calcium is the most abundant 
mineral in the body, and together with phosphorous, they comprise over 90% of the minerals in 
bone (15). The homeostatic balance of calcium and phosphorus are tightly regulated and 
maintained by complex interactions of hormonal and non-hormonal factors, dietary intake and 
functional abilities of the renal, gastrointestinal and skeletal systems (14).  
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Figure 2. Role of calcitriol in mineral homeostasis in adults. 
Mineral homeostasis is regulated by calcitriol and PTH actions in the intestines, bone and 
kidneys. (+) and (-) signs mean stimulate and inhibit, respectively. An increase in calcium 
suppresses PTH secretion while an increase in phosphorus stimulates it. Calcitriol increases 
intestinal calcium absorption and renal calcium reabsorption. PTH increases phosphorus 
excretion by kidneys and promotes renal calcium reabsorption. Calcitriol interacts with PTH and 
FGF23 to maintain Ca and P. An increase in serum Ca inhibits PTH while a decrease in serum 
Ca or a rise in serum P stimulates it. Reproduced with permission (12) Appendix B. 
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1.3.1 Role of Calcitriol in Calcium and Phosphorus Homeostasis in Adults and Fetuses 
1.3.1.1 Calcitriol and Calcium Homeostasis in Adults 
Calcium is an essential element in bone mineralization and plays a critical role in many 
biological functions including cell signaling and cellular membrane integrity, muscle 
contractions, nerve function, glycogen metabolism, and blood clotting (13,14,16). In adults, the 
human body contains about 1000 g of calcium, ~99% of which is located in the mineral phase of 
bone as hydroxyapatite crystals [Ca10 (PO4)6 (OH)2 (17)]. The remaining 1% of the total calcium 
in the body is located in the blood, extracellular fluids and soft tissues (16). Calcium in the blood 
is normally transported in a free/ionized state (45%), bound to phosphate/citrate (10%) and 
bound to plasma proteins (45%) (13).  
 
In adults, serum calcium (Ca2+) concentrations are tightly regulated by actions of the Ca2+-
sensing receptor (CaSR), PTH and calcitriol (18), with each of these hormones networked by a 
modulatory feedback loop mechanism. Serum calcium levels are mainly maintained by the 
CaSR, which belongs to the family C of G-protein-coupled receptors located in the parathyroid 
gland. The CaSR directly regulates calcium reabsorption in the kidneys. Low serum Ca2+ 
concentrations lead to less activation of CaSR (18). The resultant increase in PTH hormone 
further stimulates the production of calcitriol, which regulates intestinal calcium absorption and 
kidney calcium reabsorption (19). Calcitriol also suppresses PTH by increasing serum Ca2+ 
concentration, which acts on the CaSR in the parathyroid gland (16). PTH can also reduce renal 
calcitriol degradation by reducing the half-life of CYP24A1 mRNA (20). In the enterocytes of the 
intestinal tract, calcitriol increases the expression of the transient receptor potential cation 
channel, subfamily V, member 6 (TRPV6), and plasma membrane Ca2+ ATPase (PMCA1), 
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thereby facilitating transcellular calcium uptake (1). At the renal distal tubules, calcitriol 
increases the intracellular expression of calbindin-D28K, expression of TRPV member 5 (TRPV5) 
at the apical membrane, and expression of the ATP-dependent calcium transporter at the 
basolateral membrane, resulting in enhanced PTH-dependent calcium-reabsorption from the 
glomerular filtrate (21). Calcitriol is also known to upregulate klotho, a co-factor in the FGF23 
signalling pathway, and on the contrary, the loss of klotho results in the induction of Cyp27b1 
and calcitriol (22). The latter notion is supported by in vivo findings showing hyperphosphatemia 
and increased calcitriol in Klotho-deficient mice and Fgf23-deficient mice (22). The normal 
serum calcium levels in Klotho- and Fgf23-deficient mice validate the notion that FGF23 does 
not play a role in calcium homeostasis (19). Although, a study by Andrukhova O, et al, reported 
that FGF23 enhances calcium reabsorption in kidneys through the TRPV5 channel (23). 
 
It is well established that the physiological actions of calcitriol are mediated by its actions on the 
VDR, encoded by the VDR gene (5). Studies in humans have shown reduced 
calcium absorption in patients with severe vitamin D deficiency (24,25), specifically 
when secondary hyperparathyroidism is unable to maintain serum calcitriol levels. Indeed, 
mutations of VDR (26,27) and CYP27B1 (28,29) in humans have been known to cause severe 
hypocalcemia as well as secondary hyperparathyroidism and hypophosphatemia. To date, several 
rodent models of vitamin D deficiency that mimic phenotypic characteristics observed in humans 
have been created by several groups involving the ablation of Vdr and Cyp27b1 (30).  
 
The robust role of calcitriol in calcium homeostasis is supported by findings from vitamin D-
deficient animals, and global Vdr and Cyp27b1 null mice showing reduced calcium absorption, 
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resulting in severe hypocalcemia as well as secondary hyperparathyroidism and 
hypophosphatemia (30-32). In the intestinal-specific deletion of Vdr null mice, intestinal calcium 
absorption is decreased. However, these mice show normal blood calcium, which is different 
from the systemic Vdr null mice having low levels of serum calcium (33). The normal values of 
serum calcium in the intestinal-specific deletion of Vdr null mice are the result of bone 
resorption and impaired mineralization (with high calcitriol levels affecting the mineralization 
process by osteoblasts), whereas the osteomalacia in the systemic Vdr nulls is a result of the 
hypocalcemia. However, the fact that the abnormal calcium homeostasis observed in Vdr (34) 
and Cyp27b1 null mice (35-39), and in humans (29,40,41) can be prevented by dietary calcium 
supplements suggests that the main role of calcitriol with respect to the skeleton is indirect and is 
simply to stimulate calcium and phosphorus absorption in the intestine. 
 
The homozygous ablation of Vdr and Cyp27b1 has also been shown to reduce the expression of 
calcium transport proteins, such as Trpv6 and Pmca1, thereby reducing Ca2+ absorption in the 
intestine of adult mice (42-45). Likewise, impaired renal Ca2+ reabsorption due to a reduction in 
the expression of calbindinD-9k (CaBP-9k; S100g) and Trpv5 has been documented in adult Vdr 
and Cyp27b1 null mice (30). However, the unaffected calcium absorption in Cabp-9k, Trpv5, 
Trpv6 and Pmca1b-deficient mice suggests redundancy or the involvement of mediators other 
than calcitriol in intestinal calcium absorption (30).  
 
The actions of calcitriol-VDR signalling in bone largely depend upon calcium levels. In response 
to hypocalcemia, the actions of calcitriol promote osteoclastic bone resorption by binding to 
receptors in the preosteoblastic stromal cell and stimulating the Receptor Activator of Nuclear 
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Factor-κB (RANK) /RANK ligand (RANKL) system and facilitate calcium turnover to the 
extracellular fluid (13). Calcitriol induces the expression of RANKL and suppresses the 
expression of osteoprotegerin, which inhibits the effects of RANKL (46). The calcitriol/VDR 
system may also inhibit the mineralization of bone indirectly by releasing a phosphaturic factor 
FGF23 from osteocytes (47). On the contrary, the calcitriol/VDR system increases bone 
formation in the presence of normocalcemia. Thus, the VDR specifically overexpressed in 
mature osteoblasts enhances bone formation and decreases bone resorption in vivo (48). 
Furthermore, the overexpression of VDR in osteoblasts and osteocytes has been reported to 
prevent bone loss due to vitamin D-deficiency (49). In somewhat discordant findings, the 
specific deletion of Vdr in osteoblasts has been shown to be associated with reduced bone 
resorption but to cause a 20% increase in bone mass (50). This reflects the cross-talk between 
osteoblasts and osteoclasts, and that a reduction in bone resorption can be expected to result in a 
net increase in bone mass. Overall, physiologic levels of calcitriol in mature osteoblasts are 
required to promote bone formation, with effects on osteoblast proliferation and enhanced 
mineralization, whereas higher calcitriol levels favor bone resorption (51).  
 
Taken together, calcitriol-mediated VDR signalling is required for the regulation of calcium 
homeostasis in adults by promoting intestinal absorption and bone turnover of calcium. Thus, 
calcium homeostasis in the adult human body is maintained by orchestrated actions of calcitriol, 
CaSR and PTH present in renal, gastrointestinal and skeletal tissues. 
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1.3.1.2 Calcitriol and Phosphorus Homeostasis in Adults 
Phosphorus is an important element in bone mineralization and plays a vital role in multiple 
biological processes (52). Phosphorus is mostly stored in bone (80-90%) where it binds to 
calcium to form hydroxyapatite crystals (53). The remaining (10-20%) is found in extracellular 
fluid (ECF) in the form of organic phospholipids and inorganic phosphate (Pi) (54). The normal 
blood levels of phosphorus in adults range between 2.5-4.5 mg/dl, with higher phosphorus 
concentrations usually observed in men compared to women.  
 
Phosphorus homeostasis in adults is maintained by actions of PTH, FGF23 and calcitriol that act 
on the intestines, kidneys and bone tissues (55,56).  PTH increases serum phosphate either 
directly, by stimulating bone turnover and phosphate release, or indirectly, by facilitating 
intestinal phosphate absorption via increased calcitriol production (57). On the other hand, the 
activation of renal parathyroid hormone receptor type 1 (PTHR1) by PTH and the subsequent 
activation of the cyclic adenosine monophosphate (cAMP) and phospholipase C leads to 
internalization of the sodium–phosphate cotransporters NaPi2a and NaPi2c, thereby reducing 
renal phosphate reabsorption (1,14,57). In bone cells, intermittent PTHR1 signalling stimulates 
bone formation, whereas sustained PTH/PTHR1 signalling stimulates RANKL production, 
which in turn increases the osteoclast number, bone resorption, and, subsequently, phosphate 
release (16,57).  
 
The pivotal role of FGF23 in the regulation of phosphate homeostasis was revealed when 
studying genetic disorders (discussed in detail below) where serum calcitriol was normal but the 
values were inappropriately low given that serum phosphorus was low. This led to the 
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conclusion that something was promoting renal phosphate wasting and also suppressing calcitriol 
synthesis or increasing its degradation. A loss of function mutation of FGF23 in humans (58) 
was identified. This was also observed in studies of mice lacking Fgf23 (59) or the co-receptor 
Klotho (60). FGF23 is predominantly produced by osteocytes and osteoblasts and regulated by 
serum phosphate levels and dietary phosphate intake. In the kidneys, FGF23 reduces the 
expression of NaPi2a and NaPi2c to promote phosphorous excretion. It also reduces the 
expression of CYP27B1 and increases the activity of CYP24A1 in the proximal tubules, thereby 
reducing the production and increasing the catabolism of calcitriol, respectively, in the kidneys 
(61). In this way it acts to indirectly lower phosphate absorption in the intestine (59).  
 
The overexpression of Fgf23 and injection of FGF23 into mice causes hypophosphatemia and 
reduces calcitriol levels, and, inversely, mice lacking Fgf23 have hyperphosphatemia and high 
calcitriol (30). However, an increase in FGF23 levels following the administration of calcitriol 
and subsequent to the normalization of serum calcium and phosphate levels by dietary means in 
Vdr null mice suggests the regulation of FGF23 by both calcitriol/VDR-dependent and –
independent signalling pathways (2,12,30). 
 
The discovery of various genetic causes of human hypo- and hyper-phosphatemic disorders, and 
the subsequent development of rodent models mimicking these conditions, have facilitated our 
understanding underpinning phosphate homeostatic regulation. Hypophosphatemia causes 
accumulation of osteoid in children, resulting in severe mineralization defects in the zone of 
provisional calcification in the growth plates (rickets; (54). In adults, hypophosphatemia leads to 
accumulation of osteoid in cancellous and cortical bone (osteomalacia; (54). Human 
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physiological states that affect phosphate homeostasis include autosomal dominant 
hypophosphatemic rickets (ADHR), X-linked hypophosphatemic (XLH) rickets/osteomalacia 
and hereditary hypophosphatemic rickets with hypercalciuria (HHRH), to name only a few (54). 
XLH rickets/osteomalacia is an archetypal phosphate-wasting disorder characterized by low 
serum calcitriol and normal PTH levels, in the context of low serum phosphorous, along with 
progressive skeletal abnormalities and growth retardation (62).  
 
The phenotypic and biochemical manifestations of patients with ADHR are similar to those of 
patients with XLH. However, patients with ADHR display variable incomplete penetrance of a 
renal tubular abnormality as well as the delayed onset of penetrance (63). HHRH is a rare genetic 
disease characterized by hypophosphatemia due to increased renal phosphate clearance and 
normocalcemia, and increased serum calcitriol (64). The elevated calcitriol levels enhance 
intestinal calcium absorption, increase renal calcium load and inhibit PTH, resulting in 
hypercalciuria (64).  
 
Hyperphosphatemia on the other hand is characterized by high calcitriol and increased intestinal 
phosphate absorption. Genetic disorders such as tumoral calcinosis, characterized by loss of 
FGF23, or periarticular cystic tumorous calcifications, from loss of KLOTHO, lead to elevated 
serum calcitriol and normal serum PTH levels, which causes hyperphosphatemia (65). 
Furthermore, human clinical conditions such as renal insufficiency, malignancy, drug abuse, or 
hypoparathyroidism can also lead to hyperphosphatemia (16). Specifically, several clinical 
hypophosphatemic and hyperphosphatemic conditions are known to be associated with elevated 
FGF23 levels. However, the elevated FGF23 levels observed in patients with hyperphosphatemic 
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conditions are believed to be in response to the hyperphosphatemia, rather than being the cause 
of this condition (66). And while the high FGF23 levels counteract the hyperphosphatemia by 
reducing the levels of phosphate it doesn’t lower phosphate to normal physiological levels. 
 
Unlike the major role of PTH and FGF23 in phosphate homeostasis, only ~30% of intestinal 
phosphorus absorption is regulated by the actions of calcitriol (56). Calcitriol is known to 
regulate intestinal phosphorus absorption by increasing the expression of NAPI2B (67,68). 
Calcitriol may also regulate phosphate homeostasis by increasing KLOTHO expression in the 
distal renal tubule (69). The role of the calcitriol-VDR signaling pathway in phosphorus 
homeostasis is substantiated by the presence of hypophosphatemia in Vdr and Cyp27b1 null mice 
(31,32). However, it is possible that this interpretation may be confounded by the presence of 
secondary hyperparathyroidism in Vdr and Cyp27b1 null mice, which may have contributed to 
the hypophosphatemia by suppressing NaPi2a/c transporters (70). The actions of calcitriol have 
been attributed to the maintenance of phosphate absorption in the intestine. This is evidenced by 
the complete rescue of the osteomalacia/rickets phenotype in Vdr and Cyp27b1 null mice 
(34,36,39) given a diet high in calcium and phosphorus. There is also evidence of an indirect role 
of calcitriol-VDR signaling in the maintenance of phosphorus concentrations in bone. This 
notion is further supported by the ability of calcitriol to stimulate the synthesis of FGF-23 by 
osteoblasts and osteoclasts, which acts on the kidney to promote phosphate excretion by 
decreasing the renal expression of sodium-phosphate cotransporters (NaPi2a/c; (71). It is also 
possible for calcitriol to exert its anti-rachitic effects in bone indirectly by stimulating intestinal 
calcium and/or phosphorous absorption (34). 
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1.3.1.3 Calcitriol and Mineral Homeostasis in Fetuses  
It has been established that fetal blood calcium and phosphorus homeostasis are regulated 
differently from adults. However, little is understood about this mechanism due to the obvious 
limitations in studying human fetuses. Unlike adults, the calcium and phosphorus homeostatic 
mechanism in fetuses does not appear to involve many of the hormones that have a crucial role 
in adults.  
 
A consistent finding across various mammalian fetuses, including humans, rhesus monkeys, 
sheep, cattle, rodents and pigs, is that the serum calcium concentration is maintained at 0.30 - 
0.50 mmol/L higher than in maternal serum (5,72,73). The presence of high fetal blood calcium 
levels suggests its importance in fetal physiology. However, studies involving transgenic mice 
with ablation of various calciotropic genes, such as Pthrp, Pthr1, Homeobox A3 (Hoxa3), Trpv6 
and Hoxa3/Pthrp, have demonstrated that the presence of fetal hypocalcemia, due to ablation of 
these genes, does not affect fetal viability (74-76). The reduced skeletal calcium content of 
homozygous fetuses (e.g., Pthrp-/-, Pthr1-/- and Hoxa3-/-) with hypocalcemia underlines the 
importance of high fetal serum calcium to promote normal skeleton mineralization in utero (74-
76). 
 
The high level of blood calcium in fetuses is always maintained regardless of the presence of 
maternal hypocalcemia. This notion is supported by rodent studies showing high fetal calcium 
despite maternal hypocalcemia (77), maternal vitamin D deficiency (78,79) and maternal 
thyroparathyroidectomy(80,81). Similarly, normal fetal hypercalcemia is robustly maintained 
despite maternal vitamin D deficiency or hypoparathyroidism in humans (82). In contrast, there 
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is evidence that maternal hypercalcemia raises fetal blood calcium levels, both in the acute and 
chronic manner in rodents (73).  
 
Fetal serum phosphorus levels are also maintained at ~0.50 mmol/L higher than the mother in 
humans, rats, mice, sheep and pigs (83). Fetal phosphorus levels remain unaffected despite 
maternal hypophosphatemia in rodents (84,85). However, hyperphosphatemia in pregnant rats 
and sheep has been shown to cause fetal hyperphosphatemia (73,86,87). 
Calcitriol in fetuses typically circulates <50% of the maternal value in fetal humans, rodents and 
pigs (88-90). The contribution of the fetal kidneys is significant because fetal nephrectomy 
reduced the fetal calcitriol levels in sheep and rats (91,92). In humans, umbilical artery levels of 
calcitriol are higher than umbilical venous levels, indicating the contribution of the human fetal 
kidneys (93). Maternal nephrectomy in rats also confirmed the independent synthesis of calcitriol 
in the fetal-placental unit (94). In agreement with this notion, studies have shown the expression 
of CYP27B1 and CYP24A1 by the placenta and fetal kidneys in both humans and rodents 
(73,95). 
 
Previous studies suggest that calcitriol does not cross the placenta. This evidence includes no 
significant increase in the serum calcitriol of Cyp27b1 null Hanover pigs (88) from Cyp27b1+/- 
dams and the inability of radiolabeled calcitriol to cross rat placentas (90). In contrast, calcitriol 
has been shown to cross sheep placentas (96) and perfused human placentas (97), indicating 
possible between-species differences in the ability of calcitriol to cross the placenta. 
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To date, a number of studies have established that neither vitamin D nor calcitriol are required 
for the maintenance of fetal calcium and phosphorus homeostasis (73,83). However, the pivotal 
role of calcitriol in regulating calcium and phosphorus homeostasis in neonates, children and 
adults is well-established (73,83). Fetal blood calcium and phosphorus levels remain normal 
despite severe vitamin D deficiency in rats and following homozygous ablation of Vdr and 
Cyp27b1 in mice and pigs (31,98,99). Furthermore, fetal nephrectomy in rats has also been 
shown to not affect blood calcium or phosphorus levels (100). The cord blood of human fetuses 
from severely vitamin D deficient mothers has been demonstrated to have normal calcium and 
phosphorus levels (73,83,101,102).  In a double-blind clinical and meta-analysis, the 
administration of vitamin D to pregnant mothers resulted in a significant increase in fetal levels 
of calcitriol in vitamin D-treated mothers compared to placebo-treated mothers. However, there 
was no difference in cord blood calcium or phosphorus between groups (103,104). 
 
The placenta is the main source of minerals in the fetus. Consequently, the transfer of minerals 
across placenta also contributes to fetal mineral homeostasis (105). Vdrs are expressed in the 
placenta of sheep (106), humans (107,108), rats (109) and mice (110), and in the trophoblasts 
and yolk sac of mice (73,110). Pharmacological doses of calcitriol have been shown to increase 
calcium transfer in an in-situ placental perfusion models in rats (111), guinea pigs (112), and 
sheep (111-113). Prior nephrectomy of fetal sheep reduced calcium placental transfer, with this 
effect restored following the administration of calcitriol (114). Collectively these findings 
suggest a role for calcitriol-VDR signalling in the regulation of placental mineral transport. 
However, calcitriol may not be required for placental calcium transport as calcium delivery was 
normal in severely vitamin D-deficient fetal rats (115). Both severely vitamin D-deficient rats 
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and Vdr null mice display normal placental expression of S100g and Pmca1, vital regulators of 
placental transfer of calcium (17,31,115,116). However, Vdr null fetuses have increased 
placental calcium transport, high levels of calcitriol, and increased placental expression of Pthrp 
and Trpv6 (31,117) . Thus, it plausible that the high level of calcitriol is acting through receptors 
other than the classical VDR. If so, this phenomenon could explain why placental calcium 
transport, and the expression of Pthrp and Trpv6, were increased in Vdr nulls. Alternatively, it is 
possible that calcitriol normally acts to inhibit placental calcium transport, such that the loss of 
its receptor causes an increase in the rate of transport and its associated gene expression. 
 
1.4 Skeletal Development  
The skeletal system has several functions including structural support, the protection of internal 
soft tissues, working with the muscles to allow the body to be flexible for movement, producing 
blood cells from bone marrow and maintaining serum mineral levels through the bone formation 
and resorption process (118). Bone is a highly specialized connective tissue which forms the 
skeleton of all vertebrates (119). Bone tissue is essentially composed of three major components: 
collagen fibrils, mineral particles and water (119). The mineral particles in bone are composed of 
calcium phosphate, which exists in the form of carbonated apatite in vertebrates (119). 
 
Bone is divided into two main types–cortical and trabecular. The first type, cortical bone (also 
known as compact bone) is made of numerous overlapping cylindrical units (osteons; (120). It is 
mainly found in the shafts of long bones and represents around 80% of bone mass in the human 
body. Compact bone provides the strength and structure necessary to protect the inner organs. 
The second type, cancellous or trabecular bone, has an open honeycomb structure and accounts 
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for roughly 20% of the total bone mass (120). It is found at the end of the long bones of the 
appendicular skeleton and in the vertebral bodies of the axial skeleton. It is composed of a 
meshwork of trabeculae, thereby reducing the skeletal weight without compromising strength. It 
consists of trabeculae surrounding many red marrow-filled spaces and has metabolic activities  
(121). 
Bone development in the human fetus requires approximately 30 g of calcium during gestation, 
which is actively transported across the placenta (122). The skeleton starts to form at 20 weeks 
of pregnancy, with approximately 60 mg of calcium accreted per day by 25 weeks (122). The 
calcium deposited in the fetal skeleton increases to more than 300 mg per day between the 35th-
38th weeks and gradually decreases in the 39th and 40th weeks (122). Similarly, term fetal mice 
have ~1.5-2.0 mg of calcium, ~70-80% of which is accreted during the last four days of the 19-
day gestation period (122).  
 
Patterning of the early embryonic skeleton is dependent upon a multitude of signaling pathways, 
including Hox genes, Wnts, Hedgehogs, bone morphogenetic proteins, fibroblast growth factors 
and Notch/Delta, to name only a few (123). Primary ossification centers form in the vertebrae 
and long bones between the 8th and 12th week of embryo development in humans. However, the 
bulk of mineralization does not occur until the third trimester (124). In mice, primary ossification 
centers are present in most endochondral bones at term, whereas secondary ossification centers 
only develop after birth (73).  
 
There are two important processes that occur during fetal skeletal development and the 
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formation of bone tissues (osteogenesis): 1) intramembranous (mesenchymal) ossification and 2) 
endochondral ossification. Most of the skeleton forms through the multistep process of 
endochondral bone formation, where mesenchymal progenitors differentiate into chondroblasts 
and chondrocytes. In contrast, in few places, such as the flat bones of the skull, bones form 
through the intramembranous pathway, where the mesenchymal cells differentiate directly into 
osteoblasts which then form bone (119).  
The process of endochondral ossification is triggered by the differentiation of proliferating 
chondrocytes and is followed by the invasion of osteoblast progenitors, osteoclasts, endothelial 
cells and hematopoietic cells from the perichondrium into the hypertrophic cartilage (119,123). 
Osteoblast progenitors in the perichondrium differentiate into osteoblasts, and the primary 
ossification center expands and secondary ossification centers form, resulting in formation of the 
epiphyseal growth plate (125). In the growth plates, the chondrocytes are organized into 
structural and functional zones (Figure 1) and undergo clonal expansion. With age, the growth 
plates get thinner and are eventually replaced by bone at various times after puberty in humans. 
  
Bone tissues are formed by three primary cell types: osteoblasts, osteocytes and osteoclasts. 
These cells are responsible for bone formation and degradation. Each cell type has a unique 
function and is found in different locations within bone. The osteoblasts, located along the bone 
surface, represent 4-6% of total bone cells and are mostly known for their bone formation 
function (126,127). Osteoblasts are derived from mesenchymal stem cells (MSCs) by the action 
of a multitude of cytokines. Osteoclasts make up the smallest percentage (about 1-2%) of bone 
cells in the human skeleton. These multinucleated cells are responsible for resorption and 
degradation of the mineralized bone matrix (128). Osteoclasts are derived from mononuclear 
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cells of the hematopoietic stem cell lineage (monocyte/macrophage family) (129). Osteocytes 
represent approximately 90–95% of total bone cells with a lifespan of up to 25 years (130). 
Osteocytes originate from the terminal differentiation of osteoblasts in the mineralized matrix, 
and are embedded in osteocytic lacunae (126). 
 
 
Figure 3. The growth plate in mammals. 
The growth plate includes the resting zone, the proliferating zone, the differentiating 
chondrocytes zone and a zone of hypertrophic chondrocytes. Adapted with permission from 
(131) Appendix C. 
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1.4.1 Bone Remodeling 
Bone is a metabolically-active tissue that continuously goes through remodeling processes 
throughout life. This is essential to maintain structure and provide the body with calcium and 
phosphorus when needed. Bone remodeling is a complex process involving a series of steps that 
are highly regulated by several local and systemic factors including hormones, cytokines, 
chemokines, and biomechanical stimulation (132,133). There are three phases in this process: 
initiation of bone resorption by osteoclasts, the transition (or reversal period) from resorption to 
new bone formation, and bone formation by osteoblasts (132,133).  
 
Bone remodeling starts early in fetal life, and once the skeleton is completely formed almost all 
the metabolic activity in bone is dedicated to this process. The osteoclasts, osteoblasts and 
osteocytes closely collaborate to form the basic multicellular unit (BMU; (134). Collagenase is 
secreted by lining cells to digest the unmineralized matrix layer. The bone surface is then 
reabsorbed by osteoclast cells. The resorbed area is then reformed by osteoblast cells. Once bone 
formation is complete, some of the osteoblasts differentiate into lining cells (134). 
 
The cycle of bone remodeling occurs in a specialized vascular structure called the bone 
remodeling compartment (BRC; (135). This compartment is created by bone-lining cells to offer 
a contained microenvironment for coupling and regulation of cellular activity and to avoid 
interference by local bone marrow growth factors. Further research on the BRC is required to 
completely understand the process (136). 
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1.4.2 Calcitriol-VDR signaling and bone homeostasis 
The paramount importance of calcitriol-VDR signalling in neonatal and/or adult bone 
homeostasis is evidenced by the presence of rickets or osteomalacia in patients with VDDR type 
I and II (72,73). However, as discussed previously, the complete rescue of osteomalacia/rickets 
in adult Vdr and Cyp27b1 null mice (34,36,39), and in humans with genetic mutations leading to 
absence of VDR or CYP27B1, by a diet or parenteral infusions high in calcium and phosphorus 
or vitamin D, indicates that these skeletal defects are primarily due to impaired intestinal calcium 
absorption. In support of this notion, ablation of Vdr from bone cells (chondrocytes, osteoblasts, 
or osteocytes) or ablation of Cyp27b1 in chondrocytes, does not lead to the rachitic phenotype 
(33,50,137,138). 
 
In contrast to the findings in adults and children, less is known about the role of calcitriol in fetal 
bone metabolism. In rat fetuses, the VDRs are expressed by day 13 of pregnancy in the 
condensing mesenchyme of the vertebral column and by day 17 in osteoblasts and the 
proliferating and hypertrophic chondrocytes (2). In normal human fetal bone, VDR was found to 
be expressed in the nuclei of the perichondral mesenchymal cells (osteoblastogenic cells) and in 
fetal cartilage cells at 10 – 15 weeks of gestation (139). These findings suggest a possible 
physiological role of calcitriol-VDR signalling in fetal bone homeostasis.  
 
However, studies in fetuses of vitamin D-deficient rats and Cyp27b1 null pigs have reported 
normal skeletal lengths, morphology, ash weight, mineral content and radiologic bone mineral 
content (31,83,98). The wild-type, Vdr+/-, and Vdr null fetuses of Vdr+/- mothers are also 
indistinguishable in terms of their skeletal size, morphology, and mineral content (31). On the 
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other hand, Vdr+/-, and Vdr null fetuses born from Vdr null mothers are smaller and weigh less 
than their counterparts born of Vdr+/- mothers (31). When adjusted for these size or weight 
differences, the ash weight and bone mineral content of offspring born from Vdr+/- mothers were 
no different than the offsprings of Vdr null mothers (31). It is only after weaning that Vdr null 
neonates develop hypocalcemia and rickets (82), and these consequences can be prevented if a 
diet enriched in calcium, lactose, and phosphorus is initiated prior to weaning 
(30,34,36,73,140,141). In contrast to the findings for fetal vitamin D-deficient rats, an 8-week 
vitamin D-deficient diet in guinea pigs resulted in reduced fetal body weight, bone mineral 
content, and increased osteoid with expansion of the hypertrophic zone of chondrocytes (142). 
 
The most rigorous assessment of the human fetal skeleton at birth involved babies that had died 
of obstetrical accidents. This study compared the babies of normal mothers with babies of 
mothers with osteomalacia/vitamin D deficiency. The findings from this study also showed no 
significant between-group differences in the fetal bone calcium or phosphorus levels, ash weight 
and fetal skeletal morphology (143). To test the role of vitamin D supplementation in pregnancy 
and its effects on the fetus, several randomized clinical interventions have been done. The results 
of these individual interventions (144-146), as well as meta-analyses and reviews of the studies 
have all concluded that increased fetal values of 25OHD do not change cord blood calcium, 
phosphorous, or PTH, and also have no observable skeletal effects at birth (73,104,147). 
Taken together, these preclinical and clinical findings indicate that fetal bone homeostasis does 
not require calcitriol. This is due to the fact that fetal intestines aren’t the route of calcium 
delivery and the placenta does not require calcitriol to regulate calcium transport. On the other 
hand, neonates do not require calcitriol until later after birth, when intestinal calcium absorption 
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becomes an active or calcitriol-mediated process, as opposed to the passive absorption 
manifested at birth. 
 
1.5 Rationale and Hypothesis 
The critical role of calcitriol in the regulation of calcium and bone metabolism in children and 
adults is well-established. Studies in both human and rodent models show that severe vitamin D 
deficiency and the genetic inability to make calcitriol (CYP27B1 mutation or Cyp27b1 ablation) 
or the genetic inability to respond to calcitriol (VDR mutation or Vdr ablation) results in reduced 
intestinal calcium and phosphorus absorption, hypocalcemia, hypophosphatemia, secondary 
hyperparathyroidism, and undermineralized bone (rickets in children and osteomalacia in adults) 
(6,30,73,82,140). Thus, the main function of calcitriol in children and adults appears to be 
regulation of the intestinal absorption of calcium and phosphorus, thereby supplying the minerals 
the skeleton requires. 
In contrast, less is known about the role of calcitriol in regulating mineral and bone metabolism 
during fetal development. The widespread expression of VDR and/or CYP27B1 in fetal bone 
cells (chondocytes, osteoblasts etc.,), placental trophoblasts and fetal kidneys indicate that 
calcitriol may play an important role in fetal skeletal development and mineral homeostasis 
(30,72,73,82). However, as discussed already, previous works involving fetuses of severely 
vitamin D-deficient rats, Cyp27b1 null pigs and Vdr null mice have shown normal fetal serum 
calcium, phosphorus, skeletal morphology and ash weight (30,72,73,82). In Vdr null fetuses, 
there was an increased rate of placental calcium transport, high circulating levels of calcitriol, 
increased placental expression of Pthrp and Trpv6, and normal expression of S100g and Pmca1 
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(31,117), these findings suggest that calcitriol is not required for fetal calcium or phosphorus 
homeostasis and skeletal development or mineralization. Thus, calcitriol is only required after 
birth to regulate intestinal calcium and phosphorus absorption. 
However, the incomplete absence of calcitriol in the fetuses of severely vitamin D-deficient rats 
and the high circulating levels of calcitriol in Vdr null fetuses raise other possibilities. It is 
plausible that the high levels of calcitriol in Vdr null fetuses may act through receptors rather 
than the known classical VDR. If so, this would explain the increased placental calcium transport 
and up-regulated placental expression of Pthrp and Tprv6 in the Vdr null fetuses. Alternatively, it 
is possible that calcitriol normally acts by inhibiting the placental calcium transport, such that the 
loss of its receptor causes increased placental calcium transport. 
 
As already noted, the fetuses of severely vitamin D-deficient rats still have detectable levels of 
calcitriol (115) and Vdr null mice fetuses have been reported to have high circulating levels of 
calcitriol(31,117). Thus, the discrepancies of the existing dataset in the literature can only be 
resolved by studying the fetal mineral homeostasis and bone metabolism in Cyp27b1 null 
fetuses, which would be completely devoid of calcitriol.  
 
I hypothesized that calcitriol acts solely through VDR to regulate fetal bone and mineral 
homeostasis. Consequently, Cyp27b1 null fetuses, when compared to their Cyp27b1+/- or wild 
type (WT) siblings, should have normal serum minerals, calciotropic hormone levels, skeletal 
morphology and mineral content, placental phosphorus transport, and relevant gene expression 
within the placenta and kidneys. If calcitriol inhibits placental calcium transport, then the rate of 
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transport and associated gene expression should increase as found in Vdr null fetuses. In contrast, 
if calcitriol acts through other receptors to regulate placental calcium transport, then Cyp27b1 
null fetuses (which lack calcitriol) may show normal or reduced placental calcium transport as 
compared to the increased placental calcium transport in Vdr null fetuses, which have high 
concentrations of calcitriol in their circulation. 
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2 MATERIAL & METHODS  
2.1 Cyp27b1 Knockout Mouse Model 
Mice were obtained from Dr. René St-Arnaud (McGill University, Montréal, Quebec). A Cre-
mediated excision of the Cyp27b1 gene was performed in embryonic stem cells to deactivate the 
Cyp27b1 enzyme. The Cyp27b1 null allele was created by deleting exon 8 encoding the heme 
binding domain and part of introns 7 and 8 of the Cyp27b1 gene (32). The presence of 
hypocalcemia, hypophosphatemia, hyperparathyroidism and undetectable calcitriol levels in the 
serum of adult homozygous mutants confirmed the successful inactivation of the 1α-hydroxylase 
gene (32). Heterozygous males and females were mated and generated three genotypes: wild 
type with both normal Cyp27b1 alleles (Cyp27b1+/+), heterozygous with one normal Cyp27b1 
allele and one Cyp27b1 allele ablated (Cyp27b1+/-), and null with both Cyp27b1 alleles ablated 
(Cyp27b1-/-).  
 
2.1.1 Animal Husbandry  
Mice were maintained in a facility operated by Animal Care Services of Memorial University of 
Newfoundland, in accordance with the Canadian Council on Animal Care (CCAC). Twelve-hour 
light/dark cycles consisted of light from 8:00 am to 8:00 pm and darkness from 8:00 pm to 8:00 
am. Cyp27b1+/- male and female mice were given water and a standard rodent diet (1% calcium, 
0.75% phosphorus) ad libitum. Cyp27b1 null and their WT sisters were maintained on the rescue 
diet (TekLad TD.94112; Harlan Teklad, Madison, WI) from weaning. Males were housed 
individually for breeding, while females were housed 3-4 per cage. All experiments were 
approved by the Institutional Animal Care Committee (IACC; 15-02-CK) of Memorial 
University of Newfoundland. 
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2.1.2 Mating Strategy 
The present study herein involved two mating strategies. The first mating strategy involved time-
mating of Cyp27b1+/- male and female mice to generate pregnancies with WT, Cyp27b1+/-, and 
Cyp27b1 null fetuses. The second strategy involved mating Cyp27b1 null and WT females with 
Cyp27b1+/- males to generate Cyp27b1 null and Cyp27b1+/- fetuses from Cyp27b1 null dams and 
WT and Cyp27b1+/- fetuses from WT dams. This strategy allowed us to compare Cyp27b1 null 
and Cyp27b1+/- fetuses from Cyp27b1 null dams relative to that of Cyp27b1+/- and WT fetuses 
from WT mothers. 
 
2.2 Genotyping 
The genotypes of fetal and adult mice were identified by amplification of one target identifying 
the null allele and the other identifying the WT allele sequence through polymerase chain 
reaction (PCR) and the subsequent resolution of the gene products by gel electrophoresis. The 
following sections discuss the methods of various steps involved in the genotyping. 
 
2.2.1 Animal identification and tail sample collection 
Newly-weaned mice were briefly anesthetized under isoflurane (Fisher Scientific, Burlington, 
ON), and an ear tag containing a unique letter and number was crimped into the right ear of mice 
for identification purposes. Subsequently, tail samples (~0.5 cm) from each mouse were 
collected for genomic DNA isolation. The collected tail samples were then placed in 300 µl of 
cell lysis solution and 1.5 µl of Proteinase K (Qiagen Puregene® Core Kit A; Qiagen, Toronto, 
ON), and allowed to digest over night at 55ºC. Following tail sample collection, the tail blood 
was allowed to clot prior to placing the mice back in their home cages.  
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2.2.2 Genomic DNA Isolation 
Genomic DNA was extracted from the tail samples using the Qiagen Puregene® Core Kit A, as 
per the manufacturer’s instructions. Briefly, 100 µl of protein precipitation solution was added to 
tubes containing digested tail samples. Tubes were vortexed for 20 seconds on a high speed and 
then centrifuged for 3 minutes at 16,000 x g. The supernatant was poured into a new Eppendorf 
tube containing 300 µl of 2-Propanol (Fisher Scientific, Burlington, ON). The tubes were then 
inverted 50 times to precipitate the DNA and then centrifuged for 1 minute at 16,000 x g to pellet 
the DNA. The supernatant was discarded after centrifugation, and 300 µl of 70% ethanol was 
added to the tubes to wash the DNA pellet. The tubes were inverted again several times and 
centrifuged for 1 minute at 16,000 x g. Ethanol from the tubes was drained onto a piece of 
absorbent paper, and excess ethanol was pipetted out. The tubes were left open for 5 minutes to 
allow any remaining ethanol to evaporate. Subsequently, 100 µl of DNA hydration solution was 
added and samples were vortexed for 5 seconds. The samples were then incubated at 65ºC in a 
heat block for one hour to dissolve the DNA. The isolated genomic DNA was stored at 2-8ºC 
until further experimentation. 
 
2.2.3 Polymerase Chain Reaction 
The PCR was carried out on the genomic DNA isolated from tail samples. A three-primer system 
was used to amplify gene products. The forward primer was used to detect both the null and WT 
allele, primer 2 (reverse) was used to detect the null allele, and primer 3 (reverse) was used to 
detect the Cyp27b1 WT allele (Figure 4). Reverse primers 2 and 3 is able to detect and initiate 
replication on the WT allele while the site for primer 3 is missing in the null allele. Therefore, 
the null allele can only produce a band produced by primer 1 and 2. The WT allele can produce 
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two different bands, between primer 1 and 2, and between primer 1 and 3. However, the band 
predicted by primer 1 and 3 is shorter than the one produced by primer 1 and 2, the production of 
the shorter band is favored. Therefore, the null allele corresponds to a 350bp product versus a 
250bp product for the WT allele (Figure 4).  
 
  
Figure 4. Schematic presentation of the alignment of primers used to genotype the 
Cyp27b1 mice. A 3-primer system was used to distinguish WT, Cyp27b1+/- and Cyp27b1 
null mice. Primer 1 detected both the WT and Cyp27b1 null allele, primer 3 detected the WT 
allele, and primer 2 detected the null allele. 
 
 
1 2 3 4 5 6 7 8 9Exons
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(reverse	primer)
Mutant	allele
Primer	2
(reverse	primer)
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Hormone	binding	domain
Heme binding	domain
350bp
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The primer sequences are as follows: 
 
Cyp27-1 (forward): 5’ - AAT TCC CGT GTC CCA GAC AGA GAC ATC C – 3’ 
Cyp27-2 (reverse): 5’- GGT CAT GGG CTT GAT AGG AAG AGC ACC – 3’ 
Cyp27-3 (reverse): 5’- GGG TGG GGA ATG TGA AGA AGA GGA TCT G – 3’ 
 
The PCR cocktail contained the following: 10X PCR buffer (20 mM Tris-HCL, pH 8.4, 50 mM 
potassium chloride), deoxyribose nucleotide tri-phosphates (dNTPs) (0.2 mM Deoxyadenosine-
5'-triphosphate (dATP) : 0.2 mM Deoxythymidine triphosphate (dTTP) : 0.2 mM Deoxycytidine 
triphosphate (dCTP) : 0.2 mM Deoxyguanosine triphosphate (dGTP): H2O = 1 : 1 : 1 : 1 : 1) 
(LifeTechnologies, Burlington, ON), primers (Cyp27-1, Cyp27-2, Cyp27-3) (LifeTechnologies, 
Burlington, ON), 50 mM MgCl2, 1 U Taq DNA Polymerase (0.02 U/ µL)  (LifeTechnologies, 
Burlington, ON) and deionized water. 19.5 µl of PCR cocktail was aliquoted into each labeled 
reaction tube. 2 µl of the genomic DNA sample was added and the tubes were then placed in the 
PCR machine (C1000 Touch™ Thermal Cycler; Bio-Rad, Saint-Laurent, QC). 
 
The following steps were used to amplify PCR products: Step 1: 94°C for 5 minutes to initialize 
the reaction, Step 2: 94°C for 30 seconds to denature the DNA, Step 3: 58°C for 30 seconds to 
anneal the primers, Step 4: 72°C for 30 seconds to synthesize and elongate a complementary 
strand, Step 5: return to Step 2 and repeat for 35 cycles for continued amplification, Step 6: 72°C 
for 10 minutes to elongate any remaining strands and Step 7: hold at 4°C indefinitely. 
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2.2.4 Gel Electrophoresis 
Gel electrophoresis was performed to separate and visualize the PCR products using a 1.2% 
agarose gel (1.2 g agarose (LifeTechnologies, Burlington, ON) 10 ml 10× Tris-acetate-EDTA 
buffer (TAE; 0.12 M EDTA, 0.40 M Tris, 11.5% Glacial Acetic Acid, pH 8.0), 90 ml deionized 
water and 20% SYBRTM Safe DNA Gel Stain (LifeTechnologies, Burlington, ON). The prepared 
gel was poured into a gel electrophoresis apparatus with 24-well combs and allowed to 
polymerize for 30 minutes. Subsequently, 4 µl of 6x loading dye (10 mM Tris, 0.03% 
bromophenol blue, 0.03% xylene cyanol FF, 60% glycerol, 60 mM of 0.5 M EDTA, 1.5 M 
dH2O) was added to each of the 21.5 µl PCR products. Following solidification of the gel, 15 µl 
of the PCR product-loading dye mix was loaded into each well of the gel. The gel was run at 200 
V for 20 min in a 1× TAE running buffer.  
 
The PCR products were visualized under UV light using the Kodak Gel Doc System (Kodak, 
Toronto, ON), and an image was captured using Bio-Rad Image Lab version 5.1 software. The 
presence of a single band at 250 bp indicated the mouse was WT, a single band at 350 bp showed 
the mouse was Cyp27b1 null, and the presence of both bands indicated the mouse was 
heterozygous (Figure 5).  
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Figure 5. Representative Image of PCR products resolved using Gel Electrophoresis. 
Sample PCR products were run on a 1.2% agarose gel. As indicated above, the presence of both 
250-bp and 350-bp bands represents a Cyp27b1+/- mouse, the presence of a single 250-bp band 
indicates a WT mouse, and the presence of a single 350-bp band indicates a Cyp27b1 null mouse. 
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2.3 Blood, Tissue and Amniotic Fluid collection and storage 
On embryonic day 18.5 or 17.5, whole blood was collected from the tail vein of Cyp27b1+/- 
dams. Briefly, 1 mm was cut off the tip of the tail with a surgical blade. The tail was massaged 
and blood was collected into a regular capillary tube for serum collection. The animals were then 
anesthetized with isoflurane and euthanized by cervical dislocation. A caesarean section (C-
section) was perfomed to remove the embryonic sac, and fetuses were quickly removed from the 
embryonic sac. The placentas were also collected from each fetus and placed into labeled 
Eppendorf tubes and immediately snap-frozen in liquid nitrogen and stored at -80°C. 
 
Fetal blood was collected in a regular capillary tube by making an incision in the neck with a 
razor blade. Fetuses were then euthanized by decapitation. Fetal kidneys were collected from 
fetuses and immediately snap-frozen in liquid nitrogen and stored at -80°C. The tail samples of 
the fetuses were collected for genotyping and the caracasses were stored at –20°C for ashing or 
in scintillation vials containing 10% buffered formalin (Fisher Scientific, Burlington, ON) for 
bone histomorphometric assessment. 
 
2.3.1 Serum Collection 
Capillary tubes containing maternal blood were placed in an Eppendorf tube and allowed to drain 
and blood was left to clot for serum samples. Once clotted, the tubes were then centrifuged in a 
Micro-MB microcentrifuge (Fisher Scientific, Burlington, ON) for approximately 5 minutes at 
16,000 x g to separate the serum from blood cells. The serum was pipetted into a new 0.6-ml 
tube and stored at -20°C. 
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Fetal whole blood was collected using 60-µl micro-hematocrit capillary tubes and centrifuged at 
maximum speed for 5-10 minutes. The serum was clearly separated from the blood cells. A glass 
cutter was used to cut the capillary tube at the point where the serum and the blood cells meet. 
The serum was then ejected into a 0.6-ml microcentrifuge tube using a pipet bulb and stored at -
20°C. 
2.3.2 Amniotic Fluid Collection 
A terminal C-section was carried out on pregnant Cyp27b1+/- mothers on ED 17.5 to remove the 
intact uterus from the abdomen. The amniotic fluid was collected from each fetal sac using 60-µl 
micro-hematocrit capillary tubes. The fluid samples were then transferred to 0.6-ml 
microcentrifuge tubes and stored at -20°C until further experimentation. 
 
2.4 Mineral and Skeletal Morphometric Assessment 
2.4.1 Serum and Amniotic Fluid Total Calcium Measurement 
The test principle of the assay is based on the formation of Arsenazo III-calcium complex (blue-
purple color) as a result of a reaction between Arsenazo III and calcium. The color has a 
maximal absorbance at a wavelength of 650 nm and is directly proportional to the concentration 
of calcium in the samples. The calcium levels were assessed in both undiluted serum and 
amniotic fluid samples. All samples (serum and amniotic fluid) were analyzed using the Sekisui 
Calcium assay kit, according to the manufacturer’s protocol (Sekisui, Diagnostics PEI Ltd., 
Charlottetown, PE). The samples were collected as described above. The amount of 
serum/amniotic fluid from one fetus was sufficient to provide the 10 µl volume the assay 
required. A spectrophotometer (Ultrospec 2000; Pharmacia Biotech, Piscataway, NJ) was used to 
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determine the absorbance at 650 nm. Standard solutions of known calcium concentrations 
provided in the kit were used to generate a standard curve and were subsequently used to 
determine the calcium concentrations in the unknown serum or amniotic fluid samples. 
 
2.4.2 Serum and Amniotic Fluid Inorganic Phosphate Measurement 
The principle of this assay is based on the reaction of inorganic phosphorus with ammonium 
molybdate in the presence of sulfuric acid to produce an unreduced phosphomolybdate complex. 
Following kit instructions (Sekisui Diagnostics, Charlottetown, PEI), 10 µl of undiluted serum or 
amniotic fluid were used to measure the concentration of inorganic phosphorus using a 
spectrophotometer (Ultraspec 2000, Pharmacia Biotech, Piscataway, NJ) at 340 nm. Standard 
solutions of known inorganic phosphate concentrations provided in the kit were used to generate 
a standard curve and were subsequently used to determine the inorganic phosphate 
concentrations in the unknown serum or amniotic fluid samples. 
 
2.4.3 Amniotic Fluid Magnesium 
Magnesium in amniotic fluid was assessed using a colorimetric assay. The magnesium test is 
based on a reaction between xylidyl blue-1 and magnesium ions to form a Mg-xylidyl blue 
complex (red). Following the procedure in the kit (Genzyme Diagnostics P.E.I. Inc., 
Charlottetown, PE), the results of absorbance were read at 520 nm. Amniotic fluid samples were 
measured undiluted using a spectrophotometer (Ultrospec 2000, Pharmacia Biotech, Piscataway, 
NJ) to read the absorbance at a 650-nm wavelength. 
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2.4.4 Bone Histomorphometry 
The fetal tibias were dissected from the whole fetus and embedded in paraffin by histological 
services (Health Sciences Centre, St John’s, NL). From these paraffin blocks, 5-µm serial 
sections were cut using a Leica RM 2135 microtome (Leica Biosystems Inc., Concord, ON) and 
fixed on slides for Von Kossa staining. 
 
2.4.5 Von Kossa Staining 
This method works by detecting inorganic phosphates and carbonates. However, calcium is the 
only known cation that binds to the inorganic phosphate and carbonate anions in bone tissues 
(148,149). In this method, the silver displaces calcium to create black deposits of silver 
phosphate and silver carbonate. Slides of fetal tibial sections were placed on a slide warmer 
(Fisher Scientific) for 30 minutes. To deparafinize and rehydrate the samples, the following steps 
were followed: Xylene – 2 minutes (2x), 100% Ethanol (EtOH) – 2 minutes (2x), 95% EtOH – 2 
minutes, 70% EtOH– 2 minutes, 50% EtOH – 2 minutes, and distilled water – 1 minute.  The 
slides were then incubated in a 1% aqueous silver nitrate solution and exposed directly to light 
for 60 minutes. Sections were then washed in distilled water three times for 2 minutes each. 
Following this washing, the slides were placed in a 2.5% sodium thiosulphate solution for 5 
minutes. Following further washes with water, sections were then counterstained with methyl 
green (Sigma/Aldrich, Oakville, ON) for 2 minutes. The corners of the slides were blotted on a 
paper towel to remove the excess dye solution and then washed twice in 1-butanol (Fisher 
Scientific, Burlington, ON). The sections were then washed in xylene twice (10 seconds each 
time). As a final step, Permount (Fisher Scientific, Burlington, ON) was used on the slides to 
mount the coverslips. 
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2.4.6 Fetal Ash and Skeletal Mineral Assay 
Carcasses of genotyped fetuses embryonic day (ED) 18.5 were placed in ceramic crucibles and 
then reduced to ash using an oven (Thermo Scientific Thermolyne F62735 Oval Muffle Furnace, 
Thermo Fisher Scientific, Walthan, MA) at 500°C for 24 hours. The ash of each fetus was 
carefully transferred to a piece of weighing paper and weighed on an analytical balance. The ash 
weight represents the total mineral content of the fetal skeleton. The ash was transferred into 
labelled, acid-washed 20-ml scintillation vials and stored at room temperature for mineral 
analysis.  
 
Atomic Absorption Spectroscopy was used to analyze the amount of calcium and magnesium in 
the skeletal ash. To dissolve the ash, 253 µl of nitric acid was added to each scintillation vial and 
ash was left at room temperature to dissolve. After 5 days, 9.747 mL of distilled water was added 
to each vial for a total volume of 10 mL and a concentration of 0.2 N nitric acid. The 
concentration of calcium and magnesium in the ash was measured using a 2380 atomic 
absorption flame spectrometer (Perkin-Elmer, Walthan, MA).  
 
To measure the phosphorous content in the fetal ash, a colorimetric Phosphorus-SL Assay Kit, 
described above for measuring serum phosphorous, (Sekisui Diagnostics, Charlottetown, PE) 
was used. All samples were diluted 1:10 in distilled water prior to measurement. 
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2.5 Hormone Assays 
2.5.1 PTH Enzyme-Linked Immunosorbent Assay (ELISA) 
The parathyroid hormone (PTH) concentrations in fetal and maternal serum samples were 
assessed using an Enzyme-linked ImmunoSorbent Assay (ELISA) Kit (Immunotopics Inc, San 
Clement, CA.). Briefly, the test principle was based on two-site ELISA methodology: The C-
terminal portion is detected by an anti-rat PTH antibody attached to the well surface and ready 
for biotinylation capture. The N-terminal portion is recognized by a horseradish peroxidase 
(HRP)-labeled anti-rat antibody and forms a sandwich complex with the captured antibody. The 
enzymatic activity of the antibody complex bound to the well is directly proportional to the 
amount of PTH in the sample. 20 µl of undiluted serum was added to wells of the coated plate 
and the kit protocol was followed. After substrate incubation, results were read at 450 nm in a 
microplate spectrophotometer (Epoch; Biotek, Winooski, VT) and analyzed using Gen5 software 
(Version 2.04.11, BioTek Instruments Inc, Winsooki, VT). 
 
2.5.2 Calcitriol 
On ED 18.5, fetal serum calcitriol was measured using an ELISA kit, which is a kit for detecting 
human calcitriol that cross-reacts with mouse calcitriol (Immunodiagnostic Systems, Inc, 
Gaithersburg, MD). The two-day experiment involved an initial immunoextraction to purify 
1,25OHD in serum and then a subsequent ELISA to measure calcitrol in the serum samples. The 
minimum sample size needed for this assay was 120 µl. The maximum amount of fetal serum we 
could get was ~35 µl. Therefore, three or four samples were pooled together to reach the volume 
needed for 1 sample. The test was based on binding competitions between either free 1,25OHD 
or 1,25OHD linked to biotin for a highly-specific sheep anti-1,25OHD binding site. The amount 
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of complex biotin bound to the anti-sheep antibody was inversely proportional to the 
concentration of 1,25OHD. The detection limit of the assay was 6 pmol/L. Absorbance was 
measured at 450 nm using a microplate spectrophotometer with Gen5 software (Version 2.04.11, 
BioTek Instruments Inc, Winsooki, VT). 
 
2.5.3 25-hydroxyvitamin D and 24,25-dihydroxyvitamin D 
Sera from Cyp27b1 null, Cyp27b1+/- and WT fetuses was sent to Dr. Glenville Jones’s laboratory 
(Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON) to 
measure two forms of vitamin D (25OHD and 24,25(OH)2D). 25OHD and 24,25-
dihydroxyvitamin D were measured using liquid chromatography-tandem mass spectrometry 
(LC–MS/MS). The assay methods and procedures are similar to those published previously 
(150). 
 
2.5.4 Serum Fibroblast Growth Factor 23 (FGF23) 
Fetal serum FGF23 was analyzed using an FGF23 ELISA kit (Kainos Laboratories, Tokyo, 
Japan). The principle of the assay is based on two-step ELISA. The surface of the well contains 
immobilized FGF-23 antibodies to capture FGF23. A sandwich complex forms from the first 
antibody and HRP-labeled FGF23 antibody. The enzymatic activity of the antibody complex 
bound to the well is directly proportional to the amount of FGF23 in the sample. The detection 
limit of the assay was 3 pg/ml. The absorbance at 450 nm was measured using a microplate 
spectrophotometer with Gen5 software (Version 2.04.11, BioTek Instruments Inc, Winsooki, 
VT). 
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2.6 Calcium and Phosphorus Placental Transport  
Placental calcium transport was measured using a previously published protocol (Kovacs, et al. 
1996). On day 18.5 of gestation, Cyp27b1 heterozygous dams were briefly anesthetized with 
isoflurane. 100 µl of a solution containing 50 µCi (1.85 MBq) of 45Ca and 50 µCi (1.85 MBq) of 
51Cr-EDTA in 0.9% saline was administered by intercardiac injection. After 5 minutes, the 
mother was euthanized by cervical dislocation and a C-section was carried out to remove the 
fetuses. Each fetus was quickly removed from its amniotic sac and a tail snip was taken for 
genotyping. The fetus was then placed in a 12-mm × 75-mm disposable round bottom 
polystyrene culture test tube (Fisher Scientific, Burlington, ON) and forceps were used to pith 
the brain. Tubes were capped and the 51Cr-EDTA activity in each fetus was determined using a 
1480 WIZARD™ 3” automatic gamma counter (Perkin Elmer, Guelph, ON). 1 ml of 
ScintiGest™ (Fisher Scientific, Burlington, ON) was added to the tube and the tube was 
vortexed to loosen the fetus from the walls of the tube. The contents of the tube were poured into 
disposable 20-ml scintillation vials (Fisher Scientific, Burlington, ON) and an additional 9 ml of 
ScintiGest™ was then added to each vial. The scintillation vials were then incubated in an 
isotherm oven (Fisher Scientific, Burlington, ON) at 55°C for 24 hours to solubilize. The vials 
were vortexed several times during this incubation. Once the fetuses were completely 
solubilized, 10 ml of scintillation fluid (ScintiVerse®; Fisher Scientific, Burlington, ON) and 5 
drops of glacial acetic acid (Fisher Scientific, Burlington, ON) were added. Each vial was then 
covered with aluminum foil and placed in the dark for 24 hours to reduce bioluminescence. The 
activity of 45Ca in each fetus was then measured by an LS 6500 Multi-Purpose Scintillation 
Counter (Beckman Coulter, Montreal, QC). After measuring the activity of each isotope in each 
fetus, the ratio of 45Ca to 51Cr-EDTA activity for each fetus was used to calculate the rate of 
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calcium transfer. The results were then normalized to the mean value of the heterozygotes within 
each litter. 
 
The placental phosphorus transport experiment was adapted from the previously-described Ca2+ 
transport experiment(74). The experiment was performed following the same procedure of 
placental calcium transport. On ED 18.5, pregnant Cyp27b1 heterozygous dams were briefly 
anesthetized under isoflurane and injected with 1 ml consisting of 50 µCi (1.85 MBq) of 32P and 
50 µCi (1.85 MBq) of 51Cr-EDTA in 0.9% saline intra-cardially. Following the same steps as the 
placental calcium transport experiment, the activity of each isotope was determined in each fetus. 
The ratio of 32P to 51Cr-EDTA activity for each fetus was used to calculate the phosphorus 
transfer. The ratios were then normalized to the mean value of the heterozygote fetuses within 
each litter. 
 
2.7 Gene Expression Changes in the Placenta and Fetal Kidneys 
The expression of calcium and phosphorus relevant genes was determined using quantitative 
real-time RT-PCR (qRT-PCR) in the placenta and fetal kidneys.  
 
2.7.1 RNA Extraction 
Total RNA was extracted from placentas or both kidneys using the RNeasy Midi and RNeasy 
Mini Kit (Qiagen, Toronto, ON), respectively. The RNA quality and quantity were analyzed 
using the Agilent 2100 BioAnalyzer (Agilent Technologies, Inc., St Laurent, QC) for qPCR 
analysis. 
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2.7.2 Complementary DNA (cDNA) Synthesis  
A Superscript III First-strand Synthesis System (LifeTechnologies, Burlington, ON ) was used 
for cDNA synthesis. Following the protocol in the kit, 2 µg of RNA was used for cDNA 
synthesis. The synthesis process followed these steps: 25°C for 10 minutes, 37°C for 2 hours, 
85°C for 5 minutes, and 4°C indefinitely. 
 
2.7.3 Real-Time Quantitative RT-PCR  
The gene expression in the placenta and kidneys was analyzed using TaqMan® gene expression 
primer/probe sets and universal mastermix from Applied Biosystems (LifeTechnologies, 
Burlington, ON). The primer design consisted of MGB primers with FAM dye at the 5' end and a 
non-fluorescent quencher at the 3' end. Primer/probe sets for the following genes were used: 
Cyp27b1, Cyp24a1, Calbindin-D9k (S100g), Ca2+-ATPase (Pmca1), Trpv6, Pthrp, Klotho, 
NaPi2a, b and c, and Fgf23. Following the protocol instructions in the kit, all samples were 
analyzed in triplicate. The CT (threshold cycle value) was used as a gene expression indicator 
and GAPDH was used as an endogenous control. The real-time quantitative running program 
was as follows: Step 1: 50°C for 2 minutes for UNG incubation, Step 2: 95°C for 20 seconds for 
polymerase activation, Step 3: 95°C for 1 second for denature, Step 4: 60°C for 20 seconds for 
annealing, and Step 5: Back to Step 3 and repeat 40 times. All samples were performed in 
triplicate with a reaction volume of 20 µl.  
 
2.8 Statistical Analysis 
All data were analyzed using StatPlus 5.8.3.8 for Macintosh (AnalystSoft Inc, Walnut, CA). The 
between-group differences among means were analyzed using one-way analysis of variance 
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(ANOVA) followed by a Tukey-Kramer post-hoc test. Sample sizes are indicated in parentheses 
and biochemical data are shown with ± standard error of the mean (SEM). The qPCR data were 
analyzed using the 2-ΔΔCT method and presented as mean± SD (151). 
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3 RESULTS 
The validity of the Cyp27b1 knockout mice as a rodent model of pseudo-vitamin D-deficiency is 
established by the presence of hypocalcemia, hyperparathyroidism, hypophosphatemia and 
undetectable levels of  calcitriol (32). The present study investigated the effects of fetal absence 
of Cyp27b1 on fetal mineral homeostasis, fetal-placental mineral transfer, and fetal skeletal 
morphometric features. Herein, the study assessed these parameters in Cyp27b1 mutants born 
from Cyp27b1+/- dams. A preliminary dataset was also collected from Cyp27b1 mutants born 
from Cyp27b1 null dams. 
 
3.1 Cyp27b1 NULL FETUSES FROM Cyp27b1+/-  MOTHERS 
3.1.1 Serum Mineral and Hormone Homeostasis 
The concentrations of total calcium and phosphorous were analyzed in serum collected on 
ED18.5 from fetuses of Cyp27b1 +/- male and female mating. Cyp27b1 null fetuses had normal 
levels of serum calcium when compared to their Cyp27b1+/- and WT littermates (Figure 6A). 
Similarly, there was no significant difference in the serum phosphorus levels between Cyp27b1 
null fetuses relative to that of WT and Cyp27b1+/- littermates (Figure 6B).  
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Figure 6.  Serum calcium and phosphorous in fetuses obtained from Cyp27b1+/- dams.  
There were no between-group differences in the serum (A) calcium and (B) phosphorous levels 
of the Cyp27b1 null, Cyp27b1+/- and WT fetuses obtained from Cyp27b1+/- dams. The numbers 
in parentheses indicate the number of fetuses included in the study. Means reported ± SEM. 
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Calciotropic and phosphoric hormones such as PTH and FGF23 are known to be vital mediators 
of mineral and bone metabolism(72). Herein, the changes in the levels of these hormones were 
assessed in the fetal serum to determine the functional status of calcitriol. The levels of PTH in 
the fetal serum were assessed using an ELISA kit. Our findings showed no significant (p>0.05) 
differences in the serum levels of PTH in the Cyp27b1 null fetuses compared to WT and 
Cyp27b1+/- fetuses born from the Cyp27b1+/- dams (Figure 7A). Likewise, similar observations 
were found for Cyp27b1 null fetuses, relative to that of their WT and Cyp27b1+/- littermates, in 
the serum levels of FGF23 (Figure 7B).  
 
3.1.2 Amniotic Fluid Mineral Homeostasis 
The modulation of calcitriol levels has been shown previously to have a significant impact on 
post-natal renal mineral homeostasis (73). Hence, we assessed the levels of calcium, 
phosphorous and magnesium in the amniotic fluid as it is mainly composed of fetal urine. The 
Cyp27b1 null fetuses born from Cyp27b1+/- mothers had similar levels of calcium, phosphorous 
and magnesium compared to that of WT and Cyp27b1+/-  fetuses born in the same litter (Figure 
8A, B and C).  
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Figure 7. Serum levels of PTH and FGF23 hormones in fetuses (ED 18.5) obtained 
from Cyp27b1+/- mothers.  
There were no differences in the serum levels of (A) PTH and (B) FGF23 in the Cyp27b1 mutant 
fetuses born from Cyp27b1+/-  dams. The numbers in parentheses indicate the number of fetuses 
studied. Means reported ± SEM. 
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Figure 8. The levels of calcium, phosphorous and magnesium in the amniotic fluid (ED 
17.5) of fetuses obtained from Cyp27b1+/- mothers.  
The levels of (A) calcium, (B) phosphorous and (C) magnesium in the amniotic fluid of Cyp27b1 
null fetuses did not significantly differ from their WT and Cyp27b1+/-  littermates. The numbers 
in parentheses indicate the number of fetuses studied. Means reported ± SEM. 
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3.1.3 Placental transfer of calcium and phosphorous 
The impact of the deletion of the Cyp27b1 gene on the placental transfer of calcium and 
phosphorus was assessed. There was no difference in placental calcium transport between 
Cyp27b1 null and Cyp27b1+/- fetuses or between Cyp27b1+/- and WT fetuses (Figure 9A). 
Likewise, there was no difference in the placental transport of phosphorous in the Cyp27b1 null 
fetuses compared to that of Cyp27b1+/- and WT (Figure 9B).   
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Figure 9. Placental calcium and phosphorous transfer.  
The ratio of the (A) 45Ca to 51Cr-EDTA, and (B) 32P to 51Cr-EDTA radioactivity was measured in 
each fetus at 5 minutes after maternal intracardiac injection of the isotopes to measure the 
relative transfer of (A) calcium and (B) phosphorus across the placenta in the Cyp27b1 mutant 
fetuses from the Cyp27b1+/- mother. The values are normalized to the mean of the Cyp27b1+/-  
fetuses, set at 100%, to allow comparison between the WT and Cyp27b1 null fetuses. There was 
no statistically significant difference in the placental transfer of calcium or phosphorus across all 
three genotypes. The number in parentheses represents the number of fetuses studied. Means 
reported ± SEM. 
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3.1.4 Fetal Skeletal Morphology and Mineral Content 
3.1.4.1 Bone Morphology 
To investigate the skeletal mineralization and bone development in the Cyp27b1 mutant fetuses, 
fetal tibias were sectioned and stained using Von Kossa stain. Herein, qualitative analysis of the 
stained fetal tibial bone sections showed normal distribution of mineral in both WT and Cyp27b1 
null fetuses, suggesting that the amount of mineral present in Cyp27b1 null fetal bones did not 
differ from that of their WT siblings (Figure 10). In addition, the overall cellular morphology and 
growth plates were normal in Cyp27b1 null fetuses compared to WT siblings (Figure 10). 
  
3.1.4.2 Fetal ash weight and mineral content 
Since the Von Kossa staining suggested normal mineral content in the Cyp27b1 null compared to 
WT siblings, the next step was to quantitatively confirm these results. To do this, whole bodies of 
fetuses were reduced to ash in a furnace to determine the ash weight, which reflects the mineral 
content of bone. There was no statistically significant difference in ash weight between the WT, 
Cyp27b1+/-  and Null fetuses born from Cyp27b1+/- dams (Figure 11A). Similar ash calcium 
content was observed in the WT, Cyp27b1+/- and Cyp27b1 null fetuses born to Cyp27b1+/- 
mothers (Figure 11B). Likewise, both the magnesium (Figure 11C) and phosphorus (Figure 11D) 
contents in the skeletal ash of the Cyp27b1 null fetuses did not differ significantly from that of 
the corresponding values in the WT and Cyp27b1+/-  fetuses.  
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Figure 10. Von Kossa staining of tibias and growth plates that have been counter-
stained with methyl green. 
WT and Cyp27b1 null fetuses (ED 18.5) were obtained from Cyp27b1+/- mothers. Representative 
von Kossa-stained WT and Cyp27b1 null fetal tibial sections show normal lengths, cellular 
morphology in the chondrocytic and bone compartments and mineral content. 
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Figure 11. Fetal ash weight and mineral contents (ED 18.5).  
The whole bodies of the Cyp27b1 mutant fetuses were reduced to ash to assess the (A) weight of 
the ash and mineral contents of (B) calcium, (C) Magnesium and (D) Phosphorous. There were 
no between-group differences in any of the parameters assessed herein. The number in 
parentheses represents the number of fetuses studied. Means reported ± SEM. 
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3.1.5 Relative expression of Calciotropic and Phosphotropic genes in the placenta and 
fetal kidneys 
Changes in gene expression of several calciotropic and phosphotropic genes in the placenta and 
fetal kidneys of the WT and Cyp27b1 null fetuses were determined using qRT-PCR. Relevant 
genes were measured in the placenta and in fetal kidneys. 
 
The expression of Cyp27b1 mRNA was not absent but was significantly lower in the Cyp27b1 
null placenta compared to that of WT (Table 1). This observation is likely confounded due to the 
presence of maternal cells in the placenta. The absence of Cyp27b1 mRNA in the fetal kidneys 
of Cyp27b1 null fetuses confirms the successful deletion of this gene (Table 2). Interestingly, 
qPCR showed no significant changes in the expression of calciotropic and phosphotropic genes 
in the placenta and fetal kidneys assessed herein (Table 1 and 2). However, there was a 
significant decrease in the Pthrp gene expression in the Cyp27b1 null placentas and Cyp24a1 
fetal kidneys, respectively, compared to WT fetuses (Table 1 and 2).  
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Table 1. Gene Expression by qPCR in Cyp27b1 null placentas relative to WT collected 
from Cyp27b1+/- mothers (ED 18.5). Tests were performed in triplicate and normalized 
to a GAPDH control (n=5).  
Gene Symbol Cyp27b1 null vs. WT (Fold change ± SD) p-value 
Cyp27b1 0.459 ± 0.191 vs. 1.000 ± 0.449 <0.001 
Cyp24a1 1.249 ± 1.058 vs. 1.000 ± 0.982 NS 
Trpv6 1.018 ± 0.291 vs. 1.000 ± 0.195 NS 
PthrP 0.645 ± 0.494 vs. 1.000 ± 0.399 <0.001 
S100 1.084 ± 0.131 vs. 1.000 ± 0.445 NS 
Pmcab1 0.976 ± 0.055 vs. 1.000 ± 0.177 NS 
Klotho 1.073 ± 0.150 vs. 1.000 ± 0.305 NS 
FGF23 1.408 ± 0.809 vs. 1.000 ± 0.379 NS 
Napi2a 1.123 ± 0.289 vs. 1.000 ± 0.348 NS 
Napi2b 1.068 ± 0.433 vs. 1.000 ± 0.449 NS 
Napi2c 1.109 ± 2.091 vs. 1.000 ± 1.575 NS   
*NS – Non-significant 
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Table 2: Gene Expression by qPCR in Cyp27b1 null fetal kidneys relative to WT 
collected from Cyp27b1+/- mothers (ED 18.5). Tests were performed in triplicate and 
normalized to a GAPDH control (n=5). 
Gene Symbol Cyp27b1 null vs. WT (Fold change ± SD) p-value 
Cyp27b1 Absent expression in null N/A 
Cyp24a1 0.033 ± 0.036 vs. 1.000 ± 0.752 0.02 
Trpv6 1.013 ± 0.158 vs. 1.000 ± 0.102 NS 
S100G 0.925 ± 0.136 vs. 1.000 ± 0.162 NS 
Pmcab1 1.104 ± 0.076 vs. 1.000 ± 0.092 NS 
NaPi2a 1.059 ± 0.183 vs. 1.000 ± 0.113 NS 
NaPi2b 1.014 ± 0.220 vs. 1.000 ± 0.195 NS 
NaPi2c 1.065 ± 0.282 vs. 1.000 ± 0.233 NS 
*NS = Non-significant; **N/A = Undetectable 
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3.1.6 Fetal Serum calcitriol, 25OHD and 24,25OH2D 
The inactivation of the Cyp27b1 gene has been previously shown to affect the levels of calcitriol 
such that adult Cyp27b1 null mutants had undetectable blood calcitriol levels. Since our 
experiments so far showed no significant differences in the serum and/or skeletal mineral 
homeostasis and/or morphology, we hypothesized that the deletion of the Cyp27b1 gene should 
make calcitriol undetectable in the Cyp27b1 null fetuses. Calcitriol was not analyzed until this 
point because calcitriol measurement required a high volume of serum sample as mentioned in 
the methods section. Since calcitriol levels can also affect the levels of its precursor 25-
hydroxyvitamin D3 (25OHD3) and metabolite 24,25-dihydroxyvitamin D3 (24,25(OH)2D3), we 
determined the fetal serum levels of these metabolites as well.  
 
The serum calcitriol levels in the Cyp27b1+/- dams were 604.7±127.8 pmoml/L (Figure 11A). 
Although there was a significant reduction in the serum calcitriol levels of Cyp27b1 null fetuses 
(171.6±40.5 pmol/L) compared to that of WT (381.8±92.0) and Cyp27b1+/- (252.1±37.1) fetuses 
born from Cyp27b1+/- dams (Figure 12A). Calcitriol wasn’t undetectable and was well above the 
detected levels observed previously in Cyp27b1 null adult mice (12.1 pmol/L; (152). This 
contradicted our hypothesis that the levels of serum calcitriol in the Cyp27b1 null fetuses would 
be undetectable. A possible explanation to this paradoxical observation is that the calcitriol may 
have crossed the placenta from the Cyp27b1+/- dams to the Cyp27b1 null fetuses. Investigation of 
the fetal serum levels in the Cyp27b1 null, Cyp27b1+/-  and WT fetuses for 25OHD and 
24,25(OH)2D (Figure 12B and Figure 12C, respectively) found no significant between-group 
differences.  
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Figure 12. Serum levels of calcitriol, 25OHD and 24,25OH2D in Cyp27b1 mutant 
fetuses born from Cyp27b1+/- dams.  
There was a significant reduction in the serum levels of calcitriol in the Cyp27b1 null fetuses 
compared to Cyp27b1+/- and WT fetuses (A) but the values remained well above the detected 
levels observed in Cyp27b1 null adult mice (dashed line). In contrast, there were no between-
group differences in the serum levels of (B) 25OHD3 and (C) 24,25OH2D3. The number in 
parentheses represents the number of fetuses studied. Means reported ± SEM. 
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3.2 Cyp27b1 NULL FETUSES FROM Cyp27b1 NULL  MOTHERS: Pilot Study 
In order to determine the possibility of transplacental transfer of calcitriol from mother to fetus, a 
preliminary study was done to study the changes in fetal mineral homeostasis of Cyp27b1 mutant 
mice born from Cyp27b1 null mothers. Data herein show that Cyp27b1 null fetuses born of 
Cyp27b1 null mothers exhibited normal serum calcium levels compared to their Cyp27b1+/- 
siblings. However, the mean levels of both were significantly increased above WT and 
Cyp27b1+/-  fetuses from WT mothers (Figure 13A). Similarly, there were no differences in the 
serum levels of phosphorous in Cyp27b1 null fetuses from Cyp27b1 null mothers when 
compared to their Cyp27b1+/- littermates or to WT and Cyp27b1+/- fetuses from WT mothers 
(Figure 13B). Comparison of the fetal ash weight of Cyp27b1 null fetuses born to Cyp27b1 null 
mothers with that of their Cyp27b1+/- siblings or Cyp27b1+/- and WT fetuses from WT dams 
showed no significant differences (Figure 14A). Likewise, no significant differences were 
observed in the fetal skeletal levels of calcium (Figure 14B), phosphorus (Figure 14C) and 
magnesium (Figure 14D) between the Cyp27b1 null and Cyp27b1+/-  fetuses born from Cyp27b1 
null dams and Cyp27b1+/- and WT fetuses born from WT dams. 
 
Due to time limitations and scope of my MSc project, further investigation of the skeletal 
morphology, the serum levels of calcitriol, PTH and FGF23 and relevant genes in the placenta 
and kidneys of the Cyp27b1 mutant fetus born to Cyp27b1 null dams was investigated by another 
MSc student. Our collective results have now been published together (153). 
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Figure 13. Serum calcium and phosphorus in fetuses obtained from Cyp27b1 null and 
WT dams.  
There were no significant differences in the serum levels of calcium (A) in the Cyp27b1 null 
fetuses born from Cyp27b1 null dams relative to that of Cyp27b1+/- littermates. However, both 
were significantly higher than those in the WT and Cyp27b1+/- fetuses of WT mothers. Serum 
phosphorus (B) was similar in Cyp27b1 null fetuses born from Cyp27b1 null dams compared to 
Cyp27b1+/- littermates and to the WT and Cyp27b1+/- fetuses of WT mothers. The numbers in 
parentheses represent the number of fetuses studied. Means reported ± SEM. 
 
WT (9) +/- (5) +/- (15) null (21)
0.0
0.5
1.0
1.5
2.0
2.5
Se
ru
m
 C
al
ci
um
 
(m
m
ol
/L
)
WT (9) +/- (5) +/- (15) null (21)
0
1
2
3
Se
ru
m
 P
ho
sp
ho
ru
s
(m
m
ol
/L
)
WT dams WT damsnull dams null dams
A B
p<0.01
p<0.001
p<0.02
63 
 
 
Figure 14. Fetal ash weight and skeletal mineral contents (ED 18.5).  
The whole bodies of the Cyp27b1 mutant fetuses born from Cyp27b1 null and WT dams were 
reduced to ash to assess the (A) weight of the ash and the mineral contents of (B) calcium, (C) 
magnesium and (D) phosphorous. There were no between genotype-group differences in any of 
the parameters assessed herein. The number in parentheses represents the number of fetuses 
studied. Means reported ± SEM. 
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4 Discussion 
The present study examined the role of calcitriol in fetal mineral and bone metabolism by 
studying the consequences of ablating the Cyp27b1 gene, which encodes the 1α-hydroxylase 
enzyme that synthesizes calcitriol. Overall, Cyp27b1 null fetuses born from Cyp27b1+/- dams 
exhibited normal serum and amniotic fluid calcium and phosphorus, serum PTH and FGF23, 
placental transport of calcium and phosphorus, and normally-developed skeletons with normal 
mineral content. However, the Cyp27b1 null fetuses had low rather than undetectable serum 
calcitriol, likely due to transplacental transfer of calcitriol from the mother. Thus, in retrospect, 
this wasn’t a study of true absence of calcitriol.  
 
It is well known that calcitriol has a critical role in regulating mineral homeostasis and bone 
development in both neonates and adults (73). Low levels of calcitriol cause hypocalcemia, 
hypophosphatemia, hyperparathyroidism, and lead to rickets in children and osteomalacia in 
adults (72). To date, very few studies have examined the role of calcitriol in fetal mineral and 
bone metabolism (31,77,88,91,148,154-156). Previous work by others involving VDR ablation 
models have shown that Vdr null fetuses have normal serum minerals, PTH and skeletal 
morphology and mineralization (31,88). Human data also support that calcitriol may not play an 
essential role in regulating fetal mineral homeostasis (157). However, Vdr null fetuses exhibited 
a significant increase in placental calcium transport and serum calcitriol compared to their Vdr+/-  
and WT siblings (31). A similar result was found by a group in Belgium, where Vdr null females 
were mated to Vdr+/- males, which generated only Vdr null and Vdr+/- fetuses. The study showed 
that Vdr null fetuses had increased placental calcium transport compared to their Vdr+/- siblings 
(31,117). This increase in placental calcium transport in the absence of VDR is possibly 
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mediated through non-VDR pathways. Therefore, the present study aimed to investigate the role 
of calcitriol in fetal bone and mineral homeostasis in mice lacking calcitriol, the Cyp27b1 
knockout model (32). 
  
My findings demonstrated normal fetal serum calcium, phosphorus, PTH, skeletal morphology, 
skeletal ash weight and ash mineral content in Cyp27b1 null fetuses. These findings are in 
agreement with that of previous work by others using progenies of rodents with disrupted 
vitamin D physiology due to lack vitamin D, VDR or calcitriol, such as severely vitamin D-
deficient rats (155,156), 1α-hydroxylase null pigs (88), and Vdr+/- and Vdr  null mice (31,73). 
Taken together, these findings would imply that Cyp27b1 nulls and Vdr nulls should be identical. 
Contrary to this notion, striking differences in their function and gene expression have been 
reported and are discussed in sections below. In addition to these differences, previous studies 
have also reported reduced serum FGF23 levels in Vdr null fetuses (117,158) in comparison to 
my findings showing normal serum FGF23 levels in Cyp27b1 null fetuses. 
 
Earlier studies using the offspring of vitamin D-deficient rats did not assess placental calcium 
transfer (155,156). Hence, we further investigated the rate of calcium and phosphorus crossing 
the placenta. Consistent with our serum, amniotic fluid and skeletal mineral content findings, 
Cyp27b1 null fetuses of Cyp27b1+/- dams had similar rates of calcium and phosphorus placental 
transfer compared to their Cyp27b1+/- and WT littermates. This observation contradicts the 
notion that Cyp27b1 nulls and Vdr nulls are identical. Previous studies in our laboratory and 
another group in Belgium showed that Vdr null mice had increased placental calcium transport 
(31,117) but had normal placental phosphorus transport (159). Therefore, high levels of calcitriol 
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act primarily to increase calcium transport only in the Vdr null. Importantly, the normal placental 
calcium and phosphorous transfer in Cyp27b1 nulls, compared to the increased placental calcium 
transport in Vdr null fetuses (31), also suggest a possibility for calcitriol to regulate placental 
calcium transport through its actions on different receptors other than classic VDR. This may 
also explain why prior animal studies found that pharmacological treatment with calcitriol 
increased the rate of placental calcium transport (112-114,157). 
 
Fetal kidneys and the placenta are well known to express Cyp27b1, which converts 25-
hydroxyvitamin D3 to calcitriol (160-162). The qRT-PCR analyses of the fetal placental and 
kidney tissues demonstrated an absence of the functional Cyp27b1 mRNA in the Cyp27b1 null 
fetal kidneys and reduced Cyp27b1 mRNA in the placenta of null Cyp27b1 mice relative to that 
of the corresponding Cyp27b1 mRNA levels in tissues of WT mice. The presence of detectable 
levels of Cyp27b1 mRNA in the placenta of null Cyp27b1 fetuses is likely due to presence of 
maternal tissue. Furthermore, analyses of the expression of various calciotropic and 
phosphotropic genes in the placenta and fetal kidneys showed no significant changes in the 
expression levels of Trpv6, calbindin-D9k, Ca2+-ATPase Napi2a, Napi2b, Napi2c, Vdr, Klotho 
and Fgf23 following Cyp27b1 ablation. Normal placental expression of calbindin-D-9k and Ca2+-
ATPase and increased expression of Trpv6 in placentas of vitamin D-deficient and/or Vdr-null 
rodents has been previously demonstrated (17,31,116,154). This finding further highlights the 
difference between the Vdr null and the Cyp27b1 null fetuses, which have reduced expression of 
Cyp24a1 in the fetal kidneys. As calcitriol is the main in vivo regulator of the expression of the 
CYP24a1 enzyme that catalyzes the synthesis of 24, 25(OH)2D3, the reduction of Cyp24a1 
mRNA is not surprising given the reduction in the levels of calcitriol. In contrast to the increased 
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expression of Pthrp in the placenta of Vdr null mice (31), my findings demonstrated a reduction 
in the expression of Pthrp mRNA in the placenta of Cyp27b1 null fetuses. The low Pthrp 
expression in my studies may be attributed to the low levels of calcitriol and the high levels of 
Pthrp mRNA in Vdr nulls may be explained by the high levels of circulating calcitriol (31). 
Calcitriol typically circulates at <50% of the maternal value in fetal rodents (72). Consistent with 
this, serum levels of calcitriol in the Cyp27b1 fetuses were ~50% less than the serum calcitriol 
levels in their Cyp27b1+/- dams. In  Cyp27b1 null fetuses, we expected calcitriol to be 
undetectable as previously reported in the adult null Cyp27b1 mice (32). However, my findings 
showed reduced, but detectable, calcitriol levels in the serum of Cyp27b1 null fetuses compared 
to their WT and Cyp27b1+/- littermates born from Cyp27b1+/- dams. There were also no 
differences in the fetal serum levels of other Vitamin D metabolites such as 24,25(OH)2D3 and 
25OHD3. It is likely that calcitriol found in the serum of Cyp27b1 null fetuses was the result of 
placental transfer from their Cyp27b1+/- dams. However,  prior studies in Hanover pigs (88) and 
rats (90) have suggested that calcitriol does not cross the placenta. In contrast, my notion of 
transplacental passage of calcitriol is supported by work involving placentas from human (97) 
and lambs (96), which demonstrated that radiolabeled calcitriol readily crosses the placenta. 
Thus, it is possible that there are inter-species differences in the ability of calcitriol to pass 
through the placenta, and this remains to be investigated systematically in mice. Moreover, since 
calcitriol and its precursor 25OHD differ by only one hydroxyl group, and since 25OHD readily 
crosses the placenta (157), it is likely that they both have this ability. Hence, to address the issue 
of transplacental transfer of calcitriol from mother to fetus, a preliminary study was conducted to 
assess fetal mineral homeostasis of Cyp27b1 null mice born from Cyp27b1-/- mothers. 
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My findings showed no significant differences in the serum phosphorous levels and skeletal 
mineral content of Cyp27b1 null fetuses born of Cyp27b1 null dams, when compared to that of 
their Cyp27b1+/-  littermates or the WT and Cyp27b1+/- fetuses of WT dams. Likewise, serum 
calcium levels of Cyp27b1 null fetuses born of null dams were no different from their Cyp27b1+/-  
littermates, but both were significantly higher than those in the WT and Cyp27b1+/- fetuses of 
WT mothers. Taken together, it is plausible that calcitriol is not required for the maintenance of 
fetal mineral and bone homeostasis. However, the fact that whether these Cyp27b1 null fetuses 
born of Cyp27b1 null dams completely lacks calcitriol remains to be investigated. Due to time 
constraints, only serum levels of calcium and phosphorus, and skeletal ash and mineral contents 
were assessed in these mice. 
 
Further investigation on the Cyp27b1 null fetuses born of Cyp27b1 null dams were undertaken 
by another MSc student, and together our findings were recently published (153). Specifically, 
Cyp27b1 null fetuses born of Cyp27b1 null dams were completely devoid of calcitriol, 
confirming that maternal transfer of calcitriol from Cyp27b1+/-  dams to their Cyp27b1 null 
fetuses, can provide calcitriol to fetuses that lack the ability to synthesize it (153).  There were 
also no differences in serum calcium and phosphorus, PTH, FGF23, renal excretion of calcium 
and phosphorus into amniotic fluid, skeletal mineral content/morphology, placental calcium 
transport, and placental expression of most calciotropic and phosphotropic genes compared to 
their littermates (153).  
 
Both of our findings, taken together, demonstrated conclusively that calcitriol does not play a 
role in fetal mineral homeostasis and skeletal development (153). These findings are in 
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agreement with all prior models of disrupted vitamin D physiology except that in Vdr null 
fetuses there is high circulating concentrations of calcitriol, increased placental calcium transport 
and increased placental expression of Pthrp and Trpv6. In contrast, Cyp27b1 null fetuses born of 
Cyp27b1 null dams display no detectable levels of calcitriol, normal placental transfer of 
calcium, and normal placental expression of Pthrp and Trpv6. These findings suggest that the 
increased levels of calcitriol in Vdr null fetuses (31) may act through a receptor or receptors 
other than classic VDR to stimulate placental calcium transport and gene expression. One 
candidate is protein disulfide isomerase family A, member 3 (Pdia3). Recent data suggested that 
this protein acts as a rapidly responsive plasma membrane receptor for calcitriol (163-167). 
Although the Pdia3 mutation is embryonically lethal in mice, the heterozygotes have a skeletal 
phenotype similar to Vdr nulls (165,166). Our findings in the published paper showed that Pdia3 
was reduced in Cyp27b1 null fetuses and increased in Vdr null fetuses implying that the high 
levels of calcitriol are possibly acting through this receptor (153). This hypothesis remains to be 
tested. 
 
4.1 Limitations 
As already noted, a significant limitation of the present study was that the Cyp27b1 null fetuses 
were not devoid of calcitriol as expected when born from Cyp27b1+/- mothers. While further 
investigation of fetal serum calcitriol levels of Cyp27b1 null fetuses born from null dams was 
necessary to establish the role of calcitriol in fetal mineral and bone homeostasis, time 
constraints precluded me completing these experiments.  
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Another limitation of the present study was that the ELISA kit used to measure the calcitriol 
levels was originally designed for human serum samples that require 500 µl of serum. However, 
as mentioned in the materials and methods, the minimum sample size required for the assay was 
120 µl. The maximum amount we could get was about 35-40 µl of fetal serum. Thus, I pooled 
three or four samples together to get the amount needed for 1 sample. This further extended the 
completion time of the project and prevented me from fully completing the Cyp27b1 null dam 
study. Furthermore, the mating strategy of WT and Cyp27b1 null mothers in the Cyp27b1 null 
dam study did not enable the WT and Cyp27b1 null fetuses to be compared within the same 
litter, since Cyp27b1 null dams had only Cyp27b1null and Cyp27b1+/- fetuses and WT dams had 
only WT and Cyp27b1+/- fetuses.  
 
It is also important to remember that there is always a possibility for physiological compensation 
following inactivation of any gene. Thus, Cyp27b1 gene inactivation may not necessarily equate 
to the absence of non-classical actions of calcitriol and does not prevent compensatory 
modulation in the expression of its related genes. Further studies involving the generation of 
mice with combined ablation of Vdr and inactivation of Cyp27b1 genes may also prove useful in 
understanding the role of calcitriol in fetal mineral homeostasis and skeletal development. 
 
4.2 Summary & conclusion 
In summary, by comparing the WT, Cyp27b1+/- and Cyp27b1 null fetuses born from Cyp27b1+/- 
mothers, our results indicate that the ablation of Cyp27b1 does not affect fetal serum and 
amniotic fluid calcium and phosphorus levels, calcium and phosphorus placental transfers, and 
skeletal development and mineral deposition. However, my findings herein do not conclusively 
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rule out the possibility of calcitriol having a role in fetal mineral and bone homeostasis. This is 
because the Cyp27b1 null fetuses born from Cyp27b1+/- dams were not devoid of calcitriol as 
expected. Therefore, while this study failed to investigate fetuses completely devoid of calcitriol, 
it confirmed that transplacental passage of calcitriol from the mother to the fetus does occur. 
Furthermore, this also suggests that CYP27B1 null human neonates (vitamin D dependent rickets 
type 1 or VDDRI) will be born with maternal calcitriol in their circulation. 
 
Whilst my preliminary findings for Cyp27b1 null fetuses born from null mothers were included 
in my thesis, the studies on these mice were systematically investigated by another student, and 
our collective results were recently published (153). Taken together, our findings demonstrated 
conclusively that calcitriol does not play a role in fetal mineral homeostasis and skeletal 
development. Furthermore, my findings herein showing normal placental calcium transport in 
Cyp27b1 null fetuses, compared to increased placental calcium transport in Vdr null fetuses (31), 
suggest that calcitriol regulates placental calcium transport by acting through receptors other than 
classical VDRs. It is also important to remember that there is always a possibility for 
physiological compensation following ablation of any gene. Thus, Cyp27b1 gene ablation may 
not necessarily equate to the absence of non-classical actions of calcitriol and does not prevent 
compensatory modulation in the expression of its related genes. Further studies involving the 
generation of mice with combined ablation of Vdr and Cyp27b1 genes may also prove useful in 
understanding the role of calcitriol in fetal mineral homeostasis and skeletal development.  
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